<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395574</url>
  </required_header>
  <id_info>
    <org_study_id>N-113-2017</org_study_id>
    <nct_id>NCT03395574</nct_id>
  </id_info>
  <brief_title>Effect of Terlipressin on Cerebral Oxygen Saturation During Liver Transplantation</brief_title>
  <official_title>Effect of Terlipressin on Cerebral Oxygen Saturation and Cerebral Blood Flow During Living Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      in our study the investigators aim to assess the effect of terlipressin on cerebral
      oxygenation monitored by cerebral oxymetry and cerebral blood flow measured by transcranial
      doppler.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive 6ml /kg/h Ringer acetate solution as a maintenance intraoperative
      fluid. If pulse pressure variations (PPV) is more than 15%, the patient will be considered as
      fluid responder and will receive a 250-ml bolus of albumin 5% to maintain PPV ≤15%. Blood
      transfusion will be given based on a hemoglobin level (&lt; 7 g/dl) in both (control group) and
      (terlipressin group). Other blood products will be transfused guided by lab result; Fresh
      frozen plasma will be given when INR &gt; 2 and platelets will be given when platelets
      &lt;30.000/mm3. The patients will be randomly allocated into 2 groups; Group T (Terlipressin
      group) and group S (Normal saline 0.9%).

      For (terlipressin group) all patients will receive loading dose of terlipressin (1mg diluted
      with 50 ml of normal saline 0.9% solution over 30 min) and it will be maintained by
      continuous infusion at rate of 160 μg per hour (8 ml/h).

      For (control group) all patient will receive 50 ml of normal saline 0.9% solution over 30 min
      and will be maintained continuous infusion at rate of 8 ml/h.

      Drugs will be prepared by the nurse and the investigator will be blinded to the drug given.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral oxygen saturation</measure>
    <time_frame>one hour after infusion of drug</time_frame>
    <description>regional oxygen saturation assessed by cerebral oxymetry with probes applied on forehead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cerebral oxygen saturation</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>regional oxygen saturation assessed by cerebral oxymetry with probes applied on forehead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resistive index of middle cerebral artery</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by trans cranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak velocity, end diastolic velocity of middle cerebral arteries</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by trans cranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End diastolic velocity of middle cerebral arteries</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by trans cranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by arterial blood gases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCo2</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by arterial blood gases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Po2</measure>
    <time_frame>baseline 5 minutes after induction anesthesia,dissection phase 30 minutes after induction of anesthesia, 1 hour after drug infusion, 15 minutes after start of anhepatic phase, 5 minutes after reperfusion</time_frame>
    <description>assessed by arterial blood gases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Terlipressin Adverse Reaction</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>terlipressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline (control) group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>drug will be given after 30 minutes of induction of anesthesia</description>
    <arm_group_label>terlipressin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>drug will be given after 30 minutes as placebo in control group</description>
    <arm_group_label>saline (control) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA II-IV undergoing orthotopic liver transplantation.

          -  Age above 18 years.

        Exclusion Criteria:

          -  Age below 18 years.

          -  Patients on Terlipressin preoperative.

          -  Patients known allergic to Terlipressin.

          -  Portal vein thrombosis.

          -  Ischemic heart disease.

          -  Patients with T. bilirubin level above 7 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmed mohamed mokhtar, M.D</last_name>
    <role>Study Director</role>
    <affiliation>kasralainy faculty of medicine, Cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Elayashy Mohamed Ahmed Hassan, M.D</last_name>
    <phone>00201001833155</phone>
    <email>mohamedelayashy@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amr hussien sayed, M.D</last_name>
    <phone>00201223657694</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy Hospital , Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed elayashy mohamed ahmed hassan, M.D</last_name>
      <phone>00201001833155</phone>
      <email>mohamedelayashy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Czosnyka M, Brady K, Reinhard M, Smielewski P, Steiner LA. Monitoring of cerebrovascular autoregulation: facts, myths, and missing links. Neurocrit Care. 2009;10(3):373-86. doi: 10.1007/s12028-008-9175-7. Epub 2009 Jan 6. Review.</citation>
    <PMID>19127448</PMID>
  </reference>
  <reference>
    <citation>Joshi B, Brady K, Lee J, Easley B, Panigrahi R, Smielewski P, Czosnyka M, Hogue CW Jr. Impaired autoregulation of cerebral blood flow during rewarming from hypothermic cardiopulmonary bypass and its potential association with stroke. Anesth Analg. 2010 Feb 1;110(2):321-8. doi: 10.1213/ANE.0b013e3181c6fd12. Epub 2009 Dec 11.</citation>
    <PMID>20008083</PMID>
  </reference>
  <reference>
    <citation>Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010 Aug;55(8):2381-90. doi: 10.1007/s10620-010-1249-7. Epub 2010 May 28.</citation>
    <PMID>20508990</PMID>
  </reference>
  <reference>
    <citation>Joshi B, Ono M, Brown C, Brady K, Easley RB, Yenokyan G, Gottesman RF, Hogue CW. Predicting the limits of cerebral autoregulation during cardiopulmonary bypass. Anesth Analg. 2012 Mar;114(3):503-10. doi: 10.1213/ANE.0b013e31823d292a. Epub 2011 Nov 21.</citation>
    <PMID>22104067</PMID>
  </reference>
  <reference>
    <citation>Bechstein WO, Neuhaus P. [Bleeding problems in liver surgery and liver transplantation]. Chirurg. 2000 Apr;71(4):363-8. Review. German.</citation>
    <PMID>10840602</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Elayashy Mohamed Ahmed Hassan</investigator_full_name>
    <investigator_title>lecturer of anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

